PHATPhathom Pharmaceuticals, Inc.vs its industry peers
A metric-by-metric comparison of Phathom Pharmaceuticals, Inc. against SIC 2834 — valuation, growth, profitability, quality and total return, with each figure's rank within the peer group. Every value is Go-computed from SEC filings and delayed prices; ranks are sorted positions within the group only — descriptive, not advice.
| Company | Market cap | P/E (TTM) | P/B | P/S | Revenue growth (YoY) | Earnings growth (YoY) | EBIT margin | ROE | ROIC | Piotroski F | 1y total return | Dividend yield |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| PHATThis | $659M#1 | — | — | 3.8x#1 | 216.9%#1 | 33.8%#2 | -91.4%#1 | — | — | 4#1 | — | — |
| AQST | $605M#2 | — | — | 13.6x#2 | -22.6%#2 | -89.8%#4 | -159.5%#2 | — | — | — | -6.2%#3 | — |
| STTK | $599M#3 | — | 2.8x#1 | 599.2x#3 | -82.5%#3 | 35.3%#1 | -5150.8%#3 | -23.1%#1 | — | — | 233.5%#1 | — |
| ANNX | — | — | — | — | — | -49.6%#3 | — | -111.1%#2 | — | — | 58.1%#2 | — |
Peer set: US filers sharing this company's SEC industry classification (SIC 2834). SIC is coarse — conglomerates and multi-segment companies map imperfectly. Values from SEC filings + delayed prices; ranks are within-group positions only. Market cap, P/E, P/B, P/S, 1y total return and dividend yield are computed from each member's latest snapshot price when the table is built (see as-of; snapshot prices can lag) — not live. Some peers are still being computed, so this table covers part of the group and ranks are within the rows shown; it fills in shortly. This table timed out mid-build, so it covers part of the group; ranks are within the rows shown and it fills in shortly. Table built 2026-09-16.
Source: SEC XBRL filings + delayed prices · ranks are within-group positions · For reference only · Not investment advice